IRIX Stock Analysis: Buy, Sell, or Hold?
IRIX - Iridex Corp
$1.17
-0.01 (-0.85%)
▼
5d:
-0.85%
30d:
+15.84%
90d:
-13.33%
BUY
MODERATE Confidence
Analysis Updated: Jun 22, 2026 12:00 AM ET
Earnings: Aug 11, 2026
Get Alerted When IRIX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: IRIX shows positive signals but monitor for confirmation. Market pricing in 2.0% annual growth which appears achievable. Moderate conviction.
💡 BUY OPPORTUNITY: IRIX shows positive signals but monitor for confirmation. Market pricing in 2.0% annual growth which appears achievable. Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: IRIX is currently trading at $1.17, which is considered extended relative to its 30-day fair value range of $1.03 to $1.16. The stock's valuation (Forward PE: 59.0) is in line with its historical norms (55.5). At these levels, the market is pricing in 2.0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, IRIX is in a strong downtrend. The price is approaching resistance at $1.20. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: IRIX has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $2.75 (+133.1%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, IRIX is in a strong downtrend. The price is approaching resistance at $1.20. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: IRIX has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $2.75 (+133.1%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$1.03 -
$1.16
Company Quality Score
60/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
62.9%
All Signals
- BEARISH: Price extended above range
- BULLISH: Strong technical setup (75/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 133.1% below Wall St target ($2.75)
- NEUTRAL: Market pricing in 2.0% annual earnings growth - fairly valued
Trading Range Analysis
30-Day Trading Range
$1.03 -
$1.16
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$1.01
Resistance Level
$1.20
Current Trend
Strong Downtrend
Technical data as of
Jun 9, 2026
Fundamental Context
Forward P/E (Next Year Est.)
59.00
Wall Street Target
$2.75
(+133.1%)
Revenue Growth (YoY)
-0.8%
Profit Margin
-6.2%
Valuation Premium vs History
+2.0% premium
PE vs Historical
59.0 vs 55.5
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+2.0%
(market-implied from PE analysis)
1-Year Target
$1.20
(+2%)
2-Year Target
$1.23
(+4%)
3-Year Target
$1.25
(+6%)
3-Yr Target (if PE normalizes)
(PE: 59→56)
PE COMPRESSION
$1.18
(0%)
Earnings growth offset by PE compression
Share & Embed Analysis
Last updated: June 23, 2026 10:15 AM ET
Data refreshes hourly during market hours. Next update: 11:15 AM
Data refreshes hourly during market hours. Next update: 11:15 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is IRIX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Medical Devices Stocks
Top-rated stocks in Medical Devices by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BSX
Boston Scientific Corp |
STRONG BUY
34 analysts |
$77 | 52 HOLD |
|
DXCM
DexCom Inc |
STRONG BUY
27 analysts |
$85 | 57 HOLD |
|
SYK
Stryker Corporation |
BUY
32 analysts |
$387 | 61 BUY |
|
ABT
Abbott Laboratories |
STRONG BUY
27 analysts |
$117 | 59 HOLD |
|
PODD
Insulet Corporation |
STRONG BUY
24 analysts |
$242 | 60 HOLD |
